APG-1252 combined with Cabozantinib inhibits hepatocellular carcinoma by suppressing MEK/ERK and CREB/Bcl-xl pathways.

MLA

Di, Tian, et al. “APG-1252 Combined with Cabozantinib Inhibits Hepatocellular Carcinoma by Suppressing MEK/ERK and CREB/Bcl-Xl Pathways.” International Immunopharmacology, vol. 139, Sept. 2024, p. 112615. EBSCOhost, https://doi.org/10.1016/j.intimp.2024.112615.

APA

Di, T., Luo, Q.-Y., Song, J.-T., Yan, X.-L., Zhang, L., Pan, W.-T., Guo, Y., Lu, F.-T., Sun, Y.-T., Xia, Z.-F., Yang, L.-Q., Qiu, M.-Z., Yang, D.-J., & Sun, J. (2024). APG-1252 combined with Cabozantinib inhibits hepatocellular carcinoma by suppressing MEK/ERK and CREB/Bcl-xl pathways. International Immunopharmacology, 139, 112615. https://doi.org/10.1016/j.intimp.2024.112615

Chicago

Di, Tian, Qiu-Yun Luo, Jiang-Tao Song, Xiang-Lei Yan, Lin Zhang, Wen-Tao Pan, Yu Guo, et al. 2024. “APG-1252 Combined with Cabozantinib Inhibits Hepatocellular Carcinoma by Suppressing MEK/ERK and CREB/Bcl-Xl Pathways.” International Immunopharmacology 139 (September): 112615. doi:10.1016/j.intimp.2024.112615.